As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 23, 2012
by Ransdell Pierson for Reuters:
Pfizer Inc said on Monday its experimental Alzheimer’s disease treatment failed to prove effective in one of four high-stakes late-stage trials of the medicine.
The trial involved individuals who carry a variation of a gene called ApoE4 that makes them far more likely to develop Alzheimer’s disease. Pfizer said it and its partner Johnson & Johnson will continue with three other late-stage trials of their medicine, called bapineuzumab, based upon a review by independent safety monitors.
The failed North American trial was supervised by J&J, which is also heading another Phase III trial in North America involving patients with mild to moderate Alzheimer’s disease that do not carry the ApoE4 gene variation. Pfizer is conducting a pair of overseas Phase III trials, also involving both ApoE4 carriers, and non-carriers.
Bapineuzumab, an injectable monoclonal antibody, works by attacking a protein called beta-amyloid that is believed by many researchers to be a leading cause of Alzheimer’s disease.
Most industry analysts have held out little hope that either the Pfizer/J&J drug, or a similar medicine being develped by Eli Lilly and Co called solanezumab, will succeed in their primary goals of improving cognitive and life-function for such patients that already have symptoms.
Pfizer shares were down 1.5 percent in extended trading to $23.25. U.S. traded shares of Irish drugmaker Elan, which is also a development partner, fell nearly 17 percent to $11.25. J&J shares eased 0.4 percent to $67.82.
Dementia is a growing problem for people as they age, but it often goes undiagnosed. Now investigators at Harvard-affiliated Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center have discovered and validated a marker of...
While Jeanne Beker may be best known for her work in fashion journalism and television, she’s also an Honourary Board Member of the Women’s Brain Health Initiative (WBHI), a Canadian and U.S. foundation that works to combat brain-aging diseases and protect...
People who experience post-traumatic stress disorder may be twice as likely to have dementia later in life, according to a new study — a finding with important implications for the coronavirus pandemic. The...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.